Quanterix Corp (NASDAQ:QTRX) has received a consensus rating of “Buy” from the six brokerages that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $26.50.
QTRX has been the topic of several recent research reports. ValuEngine raised shares of Quanterix from a “sell” rating to a “hold” rating in a report on Monday, April 2nd. BTIG Research reaffirmed a “buy” rating and set a $26.00 price objective on shares of Quanterix in a report on Sunday, May 13th. Finally, Zacks Investment Research raised shares of Quanterix from a “sell” rating to a “hold” rating in a report on Tuesday, May 22nd.
In other news, SVP Ernest Orticerio sold 25,000 shares of the stock in a transaction dated Tuesday, June 5th. The shares were sold at an average price of $17.15, for a total value of $428,750.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 31.60% of the company’s stock.
Quanterix traded up $0.02, hitting $16.55, during trading on Friday, according to MarketBeat Ratings. 68,100 shares of the company’s stock traded hands, compared to its average volume of 106,696. The company has a market cap of $368.71 million and a PE ratio of -1.99. Quanterix has a 12-month low of $15.30 and a 12-month high of $24.81.
Quanterix (NASDAQ:QTRX) last released its quarterly earnings data on Wednesday, May 9th. The company reported ($0.33) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.08). equities research analysts expect that Quanterix will post -1.12 EPS for the current fiscal year.
Quanterix Company Profile
Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and Quanterix SR-X, which utilizes the same technology and assay kit as the Simoa HD-1 Analyzer.
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.